Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Kolon Tissuegene Inc. is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These 2 pending office actions are distributed across 2 distinct art units, which suggests that the company's current patent applications involve different technical sub-specialties. Practitioners must be prepared to navigate the different examination cultures and procedural requirements of the 2 distinct art units. The success of the 2 pending office actions depends on addressing the specific technical standards prevalent in each of these units.
The prosecution effort involves 2 distinct examiners, meaning that each pending matter is reviewed by a different official. NIEBAUER, RONALD T is the busiest examiner for the portfolio and is responsible for 1 pending office action. With 2 distinct examiners managing the 2 pending office actions, there is no centralization of the examination process at the individual level. This fragmentation requires practitioners to tailor their advocacy to the specific preferences of NIEBAUER, RONALD T and the other assigned examiner. Effectively managing the 2 pending office actions requires a high degree of coordination across the 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, QUANG | 2 | 37.9% | +52.6% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17488785 | CARTILAGE REGENERATION USING CHONDROCYTE AND TGF-BETA | WESTON, ALYSSA G | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18134383 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION AND DISCOGENIC BACK PAIN | NGUYEN, QUANG | 91d overdue |
| 17488785 | CARTILAGE REGENERATION USING CHONDROCYTE AND TGF-BETA | WESTON, ALYSSA G | 12d |
| 18040000 | TREATMENT OF SPINAL CORD INJURY WITH PTEN INHIBITOR | NIEBAUER, RONALD T | — |
| 18134401 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION AND DISCOGENIC BACK PAIN | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1658 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18040000 | TREATMENT OF SPINAL CORD INJURY WITH PTEN INHIBITOR | NIEBAUER, RONALD T | 1658 | §103Other | Final Rejection | — | Pending | Jun 02, 2023 |
| 18134383 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION AND DISCOGENIC BACK PAIN | NGUYEN, QUANG | 1631 | §103DP | Non-Final OA | 91d overdue | Pending | Apr 13, 2023 |
| 18134401 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION AND DISCOGENIC BACK PAIN | NGUYEN, QUANG | 1631 | §103DP | Non-Final OA | — | Pending | Apr 13, 2023 |
| 17488785 | CARTILAGE REGENERATION USING CHONDROCYTE AND TGF-BETA | WESTON, ALYSSA G | 1633 | §102§103§112 | Non-Final OA | 12d | Pending | Sep 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKolon Tissuegene Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Quang Nguyen has the most, with 2 of Kolon Tissuegene Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
